LT1009-Oph-003 (Nexus)
Palmetto Retina - Thursday, July 24, 2014
Sponsor: Lpath, Inc.
A Phase 2A, Multi-center, Masked, Randomized, Comparator-Controlled study evaluating iSONEP (Sonepcizumab [LT1009]) as either monotherapy to Lucentis, Avastin or Eylea ver Read More
1
Recent Posts
Tags
Genentech Lpath Macular Edema Regeneron Diabetic Retinopathy National Eye Institute University of Pennsylvania JAEB Center for Health Research-DRCR Wet Macular Degeneration Diabetes neovascular Pan Optic Ophthotech age-related macular degeneration Dry Macular Degeneration Wet Macular Degineration Retinal Vein Occlusion
- age-related macular degeneration (11)
- Diabetes (6)
- Diabetic Retinopathy (7)
- Dry Macular Degeneration (1)
- Genentech (2)
- JAEB Center for Health Research-DRCR (1)
- Lpath (1)
- Macular Edema (2)
- National Eye Institute (1)
- neovascular (1)
- Ophthotech (1)
- Pan Optic (1)
- Regeneron (2)
- Retinal Vein Occlusion (2)
- University of Pennsylvania (1)
- Wet Macular Degeneration (7)
- Wet Macular Degineration (6)
Archive
Our Physicians
Take a few moments to meet the skilled physicians of Palmetto Retina, P.A.
